Analysis of CYP3A5*3 and CYP3A5*6 Gene polymorphisms in Indian chronic myeloid leukemia patients

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 3, 2010, Pages 781-784

  Sailaja, K ^a   Surekha, D ^a   Nageswara Rao, D ^a   Raghunadha Rao, D ^b   Vishnupriya, S ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic myeloid leukemia; CYP3A5 gene; PCR RFLP; Response; Single nucleotide polymorphism

Indexed keywords

CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 78650714562     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Aplenc R, Glatfelter W, Han P, et al (2003). CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol, 122, 240-4.
2. Au WY, Caguioa PB, Chuah C, et al (2009). Chronic myeloid leukemia in Asia. Int J Hematol, 89, 14-23.
3. Bajpai P, Tripathi AK, Agrawal D (2010). Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. Mol Cell Biochem, 336, 49-54.
4. Blanco JG, Edick MJ, Hancock ML, et al (2002). Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics, 12, 605-11.
5. Dandara C, Ballo R, Parker MI (2005). CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett, 225, 275-82.
6. Druker BJ and Lee SJ (2005). Chronic leukemias, In Devita VT, Hellman S, and Rosenberg SA (editors): Cancer, Principles and practice of Oncology. Pub Lippincott, Philadelphia, 7th edition, 2124.
7. Fukuen S, Fukuda T, Maune H, et al (2002). Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6 in a Japanese population. Pharmacogenetics, 12, 331-4.
8. Gellner K, Eiselt R, Hustert E, et al (2001). Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11, 111-21.
9. Kuehl P, Zhang J, Lin Y, et al (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 27, 383-91.
10. Kumar L (2006). Chronic myelogenous leukemia (CML). An update. Natl Med J India, 1, 5.
11. Lahiri DK, Nurnberger J (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood RFLP studies. Nucleic Acids Res, 19, 5444.
12. Liu TC, Lin SF, Chen TP, et al (2002). Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep, 9, 327-9.
13. Nogal A, Coelho A, Araujo A, et al (2007). CYP3A5*3 genotypes and advanced non-small cell lung cancer development. J Clin Oncol, 25, 21030.
14. Paulussen A, Lavrijsen K, Bohets H, et al (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics, 10, 415-24.
15. Peng B, Dutreix C, Mehring G, et al (2004). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol, 44, 158-62.
16. Petrova DT, Yaramovb N, Toshevb S, et al (2007). Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie, 30, 559-63.
17. Shen LJ, Chen FY, Wang T, et al (2008). Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 16, 26-30.
18. Varala MH, Mattila H, Ohtonen P, et al (2008). The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostrate cancer. Int J Cancer, 122, 2511-6.
19. Wilkinson GR (1996). Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm, 24, 475-90.